Table 3.
Clinicopathologic features of previously reported primary mediastinal and intrathoracic liposarcomas of large series studies.
| Published time | Case No. | Author | Gender (M:F) | Age (year) | Clinical Presentation | Size (cm) | Location | Histology | Molecular/IHC | Therapy | Follow-upInformation | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1964 | 8 | Cicciarelli, F. E.,et al (7) | 3:5 | 50 (13-70) | pain, cough, dyspnea, loss of weight | 17.8 (14-22) | 2 PM, 2 AM, 4 MC |
8 Liposarcoma | NA | 5 excision & RT, 2 excision,1 RT |
6 recurrence | 5 DOD, 3 AWD |
| 1995 | 28 | Klimstra DS, et al (8) | 16:12 | 43 (14-72) | pain, cough, dyspnea, | 15.7 (6- 40) | 28 AM | 15 WDL,7 ML,3 PL, 3 mixed-type |
NA | 28 excision | 7 (7/22) recurrence | 11 ANED, 4 AWD, 7 DOD, |
| 2007 | 24 | Hahn HP, et al. (9) | 13:11 | 58 (3-72) | Dyspnea and cough | 16 (2.2- 61) | 9 AM,7 PM, 1 SM,7 mediastinum | 10 WDL,8 DDL,2 ML,4 PL | NA | 14 complete excision, 1 marginal excision +CT, 1 RT+CT | 5 (5/15) recurrence 2 (2/15) metastasis |
11 ANED, 1 AWD, 2 DOD, 1 DFU |
| 2012 | 24 | Boland JM, et al. (10) | 13:11 | 53 (15-73) | NA | 16 (8-30) | 6 AM, 6PM, 2SM, 3 MM, 5MC, 1PS, 1AM/SM | 8 WDL,6 DDL,2 ML, 4PL,3M-PL,1 Unclassifiable type |
WDL:1/1CPM-(FISH), DDL:3/3 CPM+(FISH), ML:1/1CPM-, DDIT3-(FISH), PL:2/2 CPM-(FISH); MPL: 1/1 DDIT3-,1/1 DDIT3-, EWS-(FISH) Unclssifiable:1/1 CPM-, FUS- DDIT3-(FISH), |
22 excision | 8 (8/19) recurrence 5 (5/19) metastasis |
6 ANED, 3 AWD, 9 DOD 3 Alive |
| 2014 | 23 | Chen M, et al. (11) | 12:11 | 49 (16-72) | Chest pain, cough, dyspnea, shortness of breath | 8 (4-39) | 10mediastinum,9 PS, 4 lung | 8 WDL, 4 DDL, 8 ML,3 PL | WDL:6/8 MDM2+, 6/8 CDK4+, 8/8 S100+(IHC) DDL: 3/4 MDM2+, 3/4 CDK4+, 4/4 S100+(IHC) ML:8/8 S100+(IHC) |
17 complete excision,6 marginal excision | 9(9/17) recurrence 6 (6/23) metastasis |
10 DOD |
| 2015 | 18 | Ortega P, et al. (12) | 11:7 | 57 (29-87) | Cough, dysphagia, and chest pain | 15 (6-30) | 18 PM | 10 WDL,3 DDL, 3 ML,2 PL | WDL: 1/2 S100 +, 5/5 MDM2+(IHC); 2/2 MDM2 +(FISH) DDL: 3/3 MDM2+, 0/3 S100+(IHC) ML: 3/3 S100+, 0/3 MDM2+(IHC) |
12 complete excision, 4 marginal excesion+RT,1 RT | 3 (3/13) recurrence 3 (3/13) metastasis |
7 ANED, 3 AWD, 2 DOD, 1DFU |
| 2019 | 31 | Fu Z et al. (13) | 19:12 | 45 (20- 64) | Chest tightness | 10 (1.8-32) | 16 AM, 8PM, 5 PS, 2 lung | 6 WDL,3 DDL,13 ML,4PL,5Mixed-type | NA | 17excision,8 excision+RT,3 RT, 1 excision +CT, 2excision+RT +CT | 20 (20/31) recurrence 11 (11/31) metastasis |
18 DOD |
M, male; F, female; NA, not available; AM, anterior mediastinum; PM, posterior mediastinum; SM, superior mediastinum; MM, middle mediastinum; MC, multiple compartments; PS, pleural space; WDL, well-differentiated liposarcoma; DDL, dedifferentiated liposarcoma; ML, myxoid liposarcoma; PL, pleomorphic liposarcoma; M-PL, myxoid pleomorphic liposarcoma; IHC, immunohistochemistry; “+” positive, “-” negative; FISH, fluorescence in situ hybridization; RT, radiotherapy; CT, chemotherapy, ANED, alive with no evidence of disease; AWD, alive with disease; DFU, died from unrelated reasons; DOD, died of disease.